Sumana Devata

Coronavirus biology and replication: implications for SARS-CoV-2

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271

COVID-19 infection: the China and Italy perspectives

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?

Acute Pancreatitis

The JAK/STAT signaling pathway: from bench to clinic

The immunology of COVID-19: is immune modulation an option for treatment?

Drug-Induced Pancreatitis

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses

Glycoproteomics

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020

A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome

Carboplatin and docetaxel-induced acute pancreatitis: brief report

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents

First in Human Phase 1 Single Dose Escalation Studies of the E-Selectin Antagonist GMI-1271 Show a Favorable Safety, Pharmacokinetic, and Biomarker Profile